Alveolar rhabdomyosarcoma-Associated PAX3-FOXO1 promotes tumorigenesis via Hippo pathway suppression

Lisa E S Crose, Kathleen A. Galindo, Julie Grondin Kephart, Candy Chen, Julien Fitamant, Nabeel Bardeesy, Rex C. Bentley, Rene L. Galindo, Jen Tsan Ashley Chi, Corinne M. Linardic

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Alveolar rhabdomyosarcoma (aRMS) is an aggressive sarcoma of skeletal muscle characterized by expression of the paired box 3-forkhead box protein O1 (PAX3-FOXO1) fusion oncogene. Despite its discovery nearly two decades ago, the mechanisms by which PAX3-FOXO1 drives tumor development are not well characterized. Previously, we reported that PAX3-FOXO1 supports aRMS initiation by enabling bypass of cellular senescence checkpoints. We have now found that this bypass occurs in part through PAX3-FOXO1-mediated upregulation of RASSF4, a Ras-Association domain family (RASSF) member. RASSF4 expression was upregulated in PAX3-FOXO1-positive aRMS cell lines and tumors. Enhanced RASSF4 expression promoted cell cycle progression, senescence evasion, and tumorigenesis through inhibition of the Hippo pathway tumor suppressor MST1. We also found that the downstream Hippo pathway target Yes-Associated protein 1 (YAP), which is ordinarily restrained by Hippo signaling, was upregulated in RMS tumors. These data suggest that Hippo pathway dysfunction promotes RMS. This work provides evidence for Hippo pathway suppression in aRMS and demonstrates a progrowth role for RASSF4. Additionally, we identify a mechanism used by PAX3- FOXO1 to inhibit MST1 signaling and promote tumorigenesis in aRMS.

Original languageEnglish (US)
Pages (from-to)285-296
Number of pages12
JournalJournal of Clinical Investigation
Volume124
Issue number1
DOIs
StatePublished - Jan 2 2014

Fingerprint

Alveolar Rhabdomyosarcoma
Carcinogenesis
Neoplasms
Oncogene Fusion
Alveolar Epithelial Cells
Cell Aging
Sarcoma
Cell Cycle
Skeletal Muscle
Up-Regulation
Forkhead Box Protein O1
Cell Line
Proteins

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Crose, L. E. S., Galindo, K. A., Kephart, J. G., Chen, C., Fitamant, J., Bardeesy, N., ... Linardic, C. M. (2014). Alveolar rhabdomyosarcoma-Associated PAX3-FOXO1 promotes tumorigenesis via Hippo pathway suppression. Journal of Clinical Investigation, 124(1), 285-296. https://doi.org/10.1172/JCI67087

Alveolar rhabdomyosarcoma-Associated PAX3-FOXO1 promotes tumorigenesis via Hippo pathway suppression. / Crose, Lisa E S; Galindo, Kathleen A.; Kephart, Julie Grondin; Chen, Candy; Fitamant, Julien; Bardeesy, Nabeel; Bentley, Rex C.; Galindo, Rene L.; Ashley Chi, Jen Tsan; Linardic, Corinne M.

In: Journal of Clinical Investigation, Vol. 124, No. 1, 02.01.2014, p. 285-296.

Research output: Contribution to journalArticle

Crose, LES, Galindo, KA, Kephart, JG, Chen, C, Fitamant, J, Bardeesy, N, Bentley, RC, Galindo, RL, Ashley Chi, JT & Linardic, CM 2014, 'Alveolar rhabdomyosarcoma-Associated PAX3-FOXO1 promotes tumorigenesis via Hippo pathway suppression', Journal of Clinical Investigation, vol. 124, no. 1, pp. 285-296. https://doi.org/10.1172/JCI67087
Crose, Lisa E S ; Galindo, Kathleen A. ; Kephart, Julie Grondin ; Chen, Candy ; Fitamant, Julien ; Bardeesy, Nabeel ; Bentley, Rex C. ; Galindo, Rene L. ; Ashley Chi, Jen Tsan ; Linardic, Corinne M. / Alveolar rhabdomyosarcoma-Associated PAX3-FOXO1 promotes tumorigenesis via Hippo pathway suppression. In: Journal of Clinical Investigation. 2014 ; Vol. 124, No. 1. pp. 285-296.
@article{6811939fe913496b8895ef0b9cd1f533,
title = "Alveolar rhabdomyosarcoma-Associated PAX3-FOXO1 promotes tumorigenesis via Hippo pathway suppression",
abstract = "Alveolar rhabdomyosarcoma (aRMS) is an aggressive sarcoma of skeletal muscle characterized by expression of the paired box 3-forkhead box protein O1 (PAX3-FOXO1) fusion oncogene. Despite its discovery nearly two decades ago, the mechanisms by which PAX3-FOXO1 drives tumor development are not well characterized. Previously, we reported that PAX3-FOXO1 supports aRMS initiation by enabling bypass of cellular senescence checkpoints. We have now found that this bypass occurs in part through PAX3-FOXO1-mediated upregulation of RASSF4, a Ras-Association domain family (RASSF) member. RASSF4 expression was upregulated in PAX3-FOXO1-positive aRMS cell lines and tumors. Enhanced RASSF4 expression promoted cell cycle progression, senescence evasion, and tumorigenesis through inhibition of the Hippo pathway tumor suppressor MST1. We also found that the downstream Hippo pathway target Yes-Associated protein 1 (YAP), which is ordinarily restrained by Hippo signaling, was upregulated in RMS tumors. These data suggest that Hippo pathway dysfunction promotes RMS. This work provides evidence for Hippo pathway suppression in aRMS and demonstrates a progrowth role for RASSF4. Additionally, we identify a mechanism used by PAX3- FOXO1 to inhibit MST1 signaling and promote tumorigenesis in aRMS.",
author = "Crose, {Lisa E S} and Galindo, {Kathleen A.} and Kephart, {Julie Grondin} and Candy Chen and Julien Fitamant and Nabeel Bardeesy and Bentley, {Rex C.} and Galindo, {Rene L.} and {Ashley Chi}, {Jen Tsan} and Linardic, {Corinne M.}",
year = "2014",
month = "1",
day = "2",
doi = "10.1172/JCI67087",
language = "English (US)",
volume = "124",
pages = "285--296",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "1",

}

TY - JOUR

T1 - Alveolar rhabdomyosarcoma-Associated PAX3-FOXO1 promotes tumorigenesis via Hippo pathway suppression

AU - Crose, Lisa E S

AU - Galindo, Kathleen A.

AU - Kephart, Julie Grondin

AU - Chen, Candy

AU - Fitamant, Julien

AU - Bardeesy, Nabeel

AU - Bentley, Rex C.

AU - Galindo, Rene L.

AU - Ashley Chi, Jen Tsan

AU - Linardic, Corinne M.

PY - 2014/1/2

Y1 - 2014/1/2

N2 - Alveolar rhabdomyosarcoma (aRMS) is an aggressive sarcoma of skeletal muscle characterized by expression of the paired box 3-forkhead box protein O1 (PAX3-FOXO1) fusion oncogene. Despite its discovery nearly two decades ago, the mechanisms by which PAX3-FOXO1 drives tumor development are not well characterized. Previously, we reported that PAX3-FOXO1 supports aRMS initiation by enabling bypass of cellular senescence checkpoints. We have now found that this bypass occurs in part through PAX3-FOXO1-mediated upregulation of RASSF4, a Ras-Association domain family (RASSF) member. RASSF4 expression was upregulated in PAX3-FOXO1-positive aRMS cell lines and tumors. Enhanced RASSF4 expression promoted cell cycle progression, senescence evasion, and tumorigenesis through inhibition of the Hippo pathway tumor suppressor MST1. We also found that the downstream Hippo pathway target Yes-Associated protein 1 (YAP), which is ordinarily restrained by Hippo signaling, was upregulated in RMS tumors. These data suggest that Hippo pathway dysfunction promotes RMS. This work provides evidence for Hippo pathway suppression in aRMS and demonstrates a progrowth role for RASSF4. Additionally, we identify a mechanism used by PAX3- FOXO1 to inhibit MST1 signaling and promote tumorigenesis in aRMS.

AB - Alveolar rhabdomyosarcoma (aRMS) is an aggressive sarcoma of skeletal muscle characterized by expression of the paired box 3-forkhead box protein O1 (PAX3-FOXO1) fusion oncogene. Despite its discovery nearly two decades ago, the mechanisms by which PAX3-FOXO1 drives tumor development are not well characterized. Previously, we reported that PAX3-FOXO1 supports aRMS initiation by enabling bypass of cellular senescence checkpoints. We have now found that this bypass occurs in part through PAX3-FOXO1-mediated upregulation of RASSF4, a Ras-Association domain family (RASSF) member. RASSF4 expression was upregulated in PAX3-FOXO1-positive aRMS cell lines and tumors. Enhanced RASSF4 expression promoted cell cycle progression, senescence evasion, and tumorigenesis through inhibition of the Hippo pathway tumor suppressor MST1. We also found that the downstream Hippo pathway target Yes-Associated protein 1 (YAP), which is ordinarily restrained by Hippo signaling, was upregulated in RMS tumors. These data suggest that Hippo pathway dysfunction promotes RMS. This work provides evidence for Hippo pathway suppression in aRMS and demonstrates a progrowth role for RASSF4. Additionally, we identify a mechanism used by PAX3- FOXO1 to inhibit MST1 signaling and promote tumorigenesis in aRMS.

UR - http://www.scopus.com/inward/record.url?scp=84892924475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892924475&partnerID=8YFLogxK

U2 - 10.1172/JCI67087

DO - 10.1172/JCI67087

M3 - Article

C2 - 24334454

AN - SCOPUS:84892924475

VL - 124

SP - 285

EP - 296

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 1

ER -